Clinical Lymphoma Myeloma and Leukemia 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Racial disparities in Mycosis Fungoides/S ézary Syndrome – A Single-center observational study of 292 patients.
In this study, we aim to characterize differences between AA/black and white patients with MF/SS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 3, 2024 Category: Hematology Authors: Ashley R. Gandham, Shamir Geller, Stephen W. Dusza, Thomas S. Kupper, Patricia. L. Myskowski Tags: Original Study Source Type: research
Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 1, 2024 Category: Hematology Source Type: research
Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 1, 2024 Category: Hematology Source Type: research
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, “dose-dense” administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2023 Category: Hematology Authors: Nicholas J. Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G. Haddad, Lewis F. Nasr, Kayleigh R. Marx, Caitlin Rausch, Jonathan M. Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian Tags: Original Study Source Type: research
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
Long-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase (CML-CP) are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40 –80% of patients with CML successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response (DMR). However, the possibility of achieving treatment-free remission after a second attempt of TKI discontinuation (TFR 2) remains unclear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 28, 2023 Category: Hematology Authors: Hiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura Tags: Review Article Source Type: research
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
The advent of tyrosine kinase inhibitors (TKIs) was revolutionary in the management of chronic myeloid leukemia (CML). Although TKIs were generally considered to be safe, they can be associated with renal injury. We evaluated the effect of TKIs on renal functions in a cohort of patients with long-term follow-up. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 27, 2023 Category: Hematology Authors: Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, HalilMete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan Tags: Original Study Source Type: research
Epidemiologic characteristics, treatment patterns, and survival analysis of Plasmablastic Lymphoma in the US: A SEER and NCDB analysis.
Plasmablastic lymphoma is a rare lymphoma associated with poor survival. We evaluated over 1,800 patients using SEER and the NCDB. Among treated patients, we described an unprecedented median overall survival of 58.6 months, and demonstrated a survival benefit for patients treated with multiagent chemotherapy. These findings will help guide clinical advances aimed at improving therapeutic options and survival outcomes for patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2023 Category: Hematology Authors: Alec R. Hansen, Victoria A. Vardell, Lindsey A. Fitzgerald Source Type: research
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
Azacitidine (AZA) is an approved frontline therapy for higher-risk myelodysplastic syndromes (HR-MDS); however, poor survival denotes unmet needs to increase depth/duration of response (DOR). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 19, 2023 Category: Hematology Authors: Nishanthan Rajakumaraswamy, Mitul Gandhi, Andrew H. Wei, David A. Sallman, Naval G. Daver, Shuyuan Mo, Shahed Iqbal, Roshan Karalliyadda, Manli Chen, Yunfei Wang, Paresh Vyas Tags: Original Study Source Type: research
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
acute lymphoblastic leukemiaallo, allogeneic (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 19, 2023 Category: Hematology Authors: Naveen Pemmaraju, Eric Deconinck, Priyanka Mehta, Irwin Walker, Marco Herling, Francine Garnache-Ottou, Nadia Gabarin, Clinton J.V. Campbell, Johannes Duell, Yakir Moshe, Tariq Mughal, Mohamad Mohty, Emanuele Angelucci Tags: Review Article Source Type: research
Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study
Autologous hematopoietic cell transplantation (autoHCT) is associated with survival benefits in multiple myeloma (MM), but utilization remains low and differs by sociodemographic factors. Prior population-based studies have not fully captured autoHCT utilization or examined relationships between sociodemographic factors and autoHCT trends over time. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 19, 2023 Category: Hematology Authors: Naseem S. Esteghamat, Ann Brunson, Aaron S. Rosenberg, Sara J. Schonfeld, Bryan Valcarcel, Renata Abrah ão, Julianne J.P. Cooley, Christa L. Meyer, Jeffery J. Auletta, Lindsay M. Morton, Lori Muffly, Ted Wun, Theresa H.M. Keegan Tags: Original Study Source Type: research
Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS)
Multiple myeloma (MM) is a blood cancer characterized by the proliferation of monoclonal plasma cells in the bone marrow, which leads to significant morbidity and mortality. MM is a life-threatening disease with debilitating symptoms of bone damage and pain, kidney failure, infections, and anemia. In the past two decades, there has been a rapid development of MM treatments and a subsequent change in drug efficacy, toxicity, long-term morbidities, and survival rates.1,2 The treatment decisions in MM patient population are increasingly guided by concerns about quality of life, achievement of cancer-free remission, living a l...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 14, 2023 Category: Hematology Authors: Anastasiia Savchenko, Joseph D. Tariman, Alexandria Kohon, Shannon D. Simonovich, Thomas Dahan, Jessica Bishop-Royse Tags: Original Study Source Type: research
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
The outcome of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has improved significantly following the introduction of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). The addition of newer-generation and more potent TKIs resulted in higher rates of molecular responses and better survival. Achieving a complete molecular remission (CMR; disappearance of the BCR::ABL1 transcripts) within the first three months of therapy is an important endpoint in newly diagnosed Ph-positive ALL that identifies patients who have an excellent long-term survival and who may not need to receive an allogeneic hematopoi...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 13, 2023 Category: Hematology Authors: Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Hagop Kantarjian Tags: Review Article Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: “Per Aspera Ad Astra”
Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developing fetus, due to their teratogenic potential. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 11, 2023 Category: Hematology Authors: Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Simona Bernardi Tags: Review Article Source Type: research
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial
Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 11, 2023 Category: Hematology Authors: Matthew Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian Flinn, Gareth P. Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S. Diefenbach, Huang Huang, Iris To, Joana Parreira, Mei Wu, Antonia Kwan, Sarit Assouline Source Type: research
SOHO State of the Art Updates and Next Questions || Chronic Myeloid Leukemia and Pregnancy: “Per Aspera Ad Astra”
Chronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developing fetus, due to their teratogenic potential. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 11, 2023 Category: Hematology Authors: Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Simona Bernardi Tags: Review Article Source Type: research
